Akèy › Kansè Poumon ki pa ti selil › Michigan › Ann Arbor
Etid klinik pou Kansè Poumon ki pa ti selil nan Ann Arbor, MI
26 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Ann Arbor (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Ap rekriteFaz 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Chelsea Hospital, Chelsea · 15 mi lwen
- ak 3 plis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- University of Michigan Rogel Cancer Center, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- ak 2 plis
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Trinity Health Ann Arbor Hospital, Ann Arbor
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- University of Michigan Health System, Ann Arbor
- Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti · 7 mi lwen
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Ap rekriteFaz 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1
- University of Michigan Health Systems, Ann Arbor
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Ann Arbor
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- University of Michigan, Ann Arbor
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- University of Michigan, Ann Arbor
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- University of Michigan, Ann Arbor
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Ap rekriteFaz 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9552), Ypsilanti · 7 mi lwen
Gilteritinib for the Treatment of ALK NSCLC
Ap rekriteFaz 1
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010, Ann Arbor
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- ak 1 plis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- University of Michigan, Ann Arbor
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Repositioning Immunotherapy in VetArans With Lung Cancer
Ap rekriteFaz 2
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- University of Michigan (Data Collection Only), Ann Arbor
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Ap rekrite
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Ap rekriteFaz 1/2
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Ann Arbor
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Ann Arbor
- Kansè nan tete27 etid
- Kansè pwostat27 etid
- Kansè (tout kalite)25 etid
- Kansè poumon23 etid
- Kansè kolorektal23 etid
- Ensifizyans kadyak22 etid
- Leksemi mieloïd egi17 etid
- Maladi kadyovaskilè16 etid
- Kansè pankreyas14 etid
- Melanom12 etid
- Akidan serebavaskilè12 etid
- Karsinòm selil skuamèz tèt ak kou12 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.